Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akira Mita

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Sensors (Basel, Switzerland)|June 2, 2021
Absolute Displacement-Based Formulation for Peak Inter-Story Drift Identification of Shear Structures Using Only One AccelerometerKangqian Xu, Akira Mita
International Scholarly Research Notices|July 30, 2016
Damage Location and Quantification Indices of Shear Structures Based on Changes in the First Two or Three Natural FrequenciesHien HoThu, Akira Mita
Sensors (Basel, Switzerland)|November 23, 2017
Markerless Knee Joint Position Measurement Using Depth Data during Stair WalkingAmi Ogawa, Akira Mita, Ayanori Yorozu, et al.
Anticancer Research|May 18, 2012
A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumorsBenjamin Friday, Yvonne Lassere, Christina A Meyers, et al.
Cancer|August 12, 2006
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumorsDavid S Hong, James L Abbruzzese, Karla Bogaard, et al.
Cancer Investigation|September 18, 2008
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumorsMichael J Overman, Scott Kopetz, Gauri Varadhachary, et al.
Investigational New Drugs|June 6, 2008
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsMichael J Overman, Gauri Varadhachary, Scott Kopetz, et al.
Investigational New Drugs|September 15, 2010
Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignanciesLisa A Hammond-Thelin, Melanie B Thomas, Michiko Iwasaki, et al.
Biochemical Pharmacology|March 12, 2010
An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulationVivian Wai Yan Lui, Cecilia Pik Yuk Lau, Crystal Sao Fong Cheung, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Sensors (Basel, Switzerland)|June 2, 2021
Absolute Displacement-Based Formulation for Peak Inter-Story Drift Identification of Shear Structures Using Only One AccelerometerKangqian Xu, Akira Mita
International Scholarly Research Notices|July 30, 2016
Damage Location and Quantification Indices of Shear Structures Based on Changes in the First Two or Three Natural FrequenciesHien HoThu, Akira Mita
Sensors (Basel, Switzerland)|November 23, 2017
Markerless Knee Joint Position Measurement Using Depth Data during Stair WalkingAmi Ogawa, Akira Mita, Ayanori Yorozu, et al.
Anticancer Research|May 18, 2012
A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumorsBenjamin Friday, Yvonne Lassere, Christina A Meyers, et al.
Cancer|August 12, 2006
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumorsDavid S Hong, James L Abbruzzese, Karla Bogaard, et al.
Cancer Investigation|September 18, 2008
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumorsMichael J Overman, Scott Kopetz, Gauri Varadhachary, et al.
Investigational New Drugs|June 6, 2008
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsMichael J Overman, Gauri Varadhachary, Scott Kopetz, et al.
Investigational New Drugs|September 15, 2010
Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignanciesLisa A Hammond-Thelin, Melanie B Thomas, Michiko Iwasaki, et al.
Biochemical Pharmacology|March 12, 2010
An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulationVivian Wai Yan Lui, Cecilia Pik Yuk Lau, Crystal Sao Fong Cheung, et al.
Pageof 1